POINT Biopharma Global (POINT Biopharma Global) Total Liabilities : $53.5 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global Total Liabilities?

POINT Biopharma Global's Total Liabilities for the quarter that ended in Sep. 2023 was $53.5 Mil.

POINT Biopharma Global's quarterly Total Liabilities declined from Mar. 2023 ($86.74 Mil) to Jun. 2023 ($50.32 Mil) but then increased from Jun. 2023 ($50.32 Mil) to Sep. 2023 ($53.51 Mil).

POINT Biopharma Global's annual Total Liabilities declined from Dec. 2020 ($8.71 Mil) to Dec. 2021 ($8.05 Mil) but then increased from Dec. 2021 ($8.05 Mil) to Dec. 2022 ($91.37 Mil).

POINT Biopharma Global Total Liabilities Historical Data

The historical data trend for POINT Biopharma Global's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global Total Liabilities Chart

POINT Biopharma Global Annual Data

Trend

Dec20

Dec21

Dec22

Total Liabilities

8.71

8.05

91.37

POINT Biopharma Global Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Liabilities	Get a 7-Day Free Trial									16.61	91.37	86.74	50.32	53.51

POINT Biopharma Global Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

POINT Biopharma Global's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	79.738	+	(0	+	1.453
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	10.178	+	0)
	=	91.4

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	578.323	-	486.954
	=	91.4

POINT Biopharma Global's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	38.666	+	(8.736	+	2.389
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	3.721	+	0)
	=	53.5

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	477.704	-	424.192
	=	53.5

POINT Biopharma Global Total Liabilities Related Terms

Thank you for viewing the detailed overview of POINT Biopharma Global's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

POINT Biopharma Global (POINT Biopharma Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

4850 West 78th Street, Indianapolis, IN, USA, 46268

Website

https://www.pointbiopharma.com

POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.

Executives

Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell	director	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann	director, officer: Chief Executive Officer	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue	director	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472